Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
Open Access
- 1 May 2018
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 94, 87-94
Abstract
No abstract availableKeywords
Funding Information
- AVEO Oncology and Astellas Pharma US, Inc
This publication has 21 references indexed in Scilit:
- Tivozanib in the treatment of renal cell carcinomaBiologics: Targets and Therapy, 2013
- An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinomaTherapeutic Advances in Urology, 2012
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell CarcinomaJournal of Clinical Oncology, 2012
- Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicitiesInvestigational New Drugs, 2012
- Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid TumorsClinical Cancer Research, 2011
- Clinically relevant fatigue in recurrence-free prostate cancer survivorsAnnals of Oncology, 2011
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007